© 2006 European Society for Medical Oncology
symposium article |
Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma
1 Department of Haematology, Westmead Hospital, Westmead NSW 2145, Australia; 2 Cancer Care Centre Nepean Hospital, NSW, Australia
* Correspondence to: Dr M. S. Hertzberg, Department of Haematology, Westmead Hospital, Westmead, NSW 2145, Australia. Tel: +61-2-9845-6274; Fax: +61-2-9689-2331; E-mail: mark_hertzberg{at}wmi.usyd.edu.au
We have treated 75 transplant-eligible patients with relapsed or refractory lymphoma using an outpatient-based fractionated regimen of ifosfamide, carboplatin and etoposide (ICE) for both salvage and stem cell mobilisation. Patients included DLBC (n = 33), follicular (n = 23), NK/T-cell (n = 3), mantle cell (n = 3) and Hodgkin's lymphoma (n = 13). Cycles of outpatient ICE were given every 21 days and consisted of: ifosfamide 5000 mg/m2 i.v. fractionated into three equally divided doses and infused over 2–3 h on days 1–3, carboplatin (mg dose = 5 x AUC) i.v. over 1 h on day 1; and etoposide 100 mg/m2 i.v. daily on days 1–3, plus filgrastim 5 µg/kg/day. Most patients with indolent lymphoma also received rituximab. The median age of patients was 52 years (range 26–69 years). Patients received a mean of 2.8 cycles of ICE. Non-haematological toxicities included grade 1/2 CNS toxicity in four patients, cardiac toxicity in two, reversible renal impairment and haematuria in one each. Haematological toxicity included grades III/IV thrombocytopenia and neutropenia with at least one cycle of ICE in 71% and 72% of patients, respectively. The median time to PBSC harvest was 14 days (range 10–20 days), while the median CD34+ cell yield was 4.8 x 106/kg (range 2.3–37.8). Five patients (7%) failed to mobilise PBSCs. The overall response rate to ICE was 89%, comprising 29% who achieved a CR and 60% who achieved a PR; for DLBCL, the overall response rate was 85% including 36% who achieved a CR and 49% who exhibited a PR. At a median follow-up of 24 months, the Kaplan–Meier estimates of the overall and event-free survival for all patients were 65% and 42%, respectively. For patients with DLBCL overall and event-free survival figures were 51% and 35%, respectively, at a median follow-up of 14 months. These data confirm the efficacy and tolerability of outpatient fractionated ICE as both a salvage and mobilisation regimen in relapsed/refractory lymphoma.
Key words: salvage, relapsed/refractory, lymphoma, transplant, mobilisation, toxicity
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Sirohi, D. Cunningham, R. Powles, F. Murphy, T. Arkenau, A. Norman, J. Oates, A. Wotherspoon, and A. Horwich Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma Ann. Onc., July 1, 2008; 19(7): 1312 - 1319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Evens, J. Altman, B. Mittal, N Hou, A Rademaker, D Patton, L Kaminer, S Williams, S Duffey, D Variakojis, et al. Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma Ann. Onc., April 1, 2007; 18(4): 679 - 688. [Abstract] [Full Text] [PDF]
|
|